Monsanto Company (MON) : Corecommodity Management reduced its stake in Monsanto Company by 1.31% during the most recent quarter end. The investment management company now holds a total of 27,214 shares of Monsanto Company which is valued at $2,669,421 after selling 361 shares in Monsanto Company , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Monsanto Company makes up approximately 2.75% of Corecommodity Management’s portfolio.
Other Hedge Funds, Including , Capital International Sarl reduced its stake in MON by selling 16,000 shares or 17.24% in the most recent quarter. The Hedge Fund company now holds 76,800 shares of MON which is valued at $7,533,312. Monsanto Company makes up approx 0.68% of Capital International Sarl’s portfolio.Linscomb Williams reduced its stake in MON by selling 53 shares or 0.46% in the most recent quarter. The Hedge Fund company now holds 11,400 shares of MON which is valued at $1,116,402. Monsanto Company makes up approx 0.11% of Linscomb Williams’s portfolio.Frontier Investment Mgmt Co reduced its stake in MON by selling 755 shares or 2.91% in the most recent quarter. The Hedge Fund company now holds 25,175 shares of MON which is valued at $2,497,108. Monsanto Company makes up approx 0.31% of Frontier Investment Mgmt Co’s portfolio.Plante Moran Financial Advisors reduced its stake in MON by selling 1,600 shares or 26.46% in the most recent quarter. The Hedge Fund company now holds 4,446 shares of MON which is valued at $439,309. Monsanto Company makes up approx 0.31% of Plante Moran Financial Advisors’s portfolio. Beck Mack Oliver sold out all of its stake in MON during the most recent quarter. The investment firm sold 4,182 shares of MON which is valued $421,420.
Monsanto Company opened for trading at $100.6 and hit $101.268 on the upside on Monday, eventually ending the session at $101.21, with a gain of 0.55% or 0.55 points. The heightened volatility saw the trading volume jump to 13,68,350 shares. Company has a market cap of $44,328 M.
On the company’s financial health, Monsanto Company reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Oct 5, 2016. Analyst had a consensus of $-0.03. The company had revenue of $2562.00 million for the quarter, compared to analysts expectations of $2379.03 million. The company’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.
Many Wall Street Analysts have commented on Monsanto Company. Shares were Reiterated by Monness Crespi & Hardt on Oct 3, 2016 to “Buy” and Lowered the Price Target to $ 128 from a previous price target of $130 .Monsanto Company was Upgraded by Goldman to ” Neutral” on Sep 27, 2016. Monsanto Company was Upgraded by Bernstein to ” Mkt Perform” on Sep 26, 2016.
Monsanto Company (Monsanto) is a provider of agricultural products for farmers. The Company’s seeds biotechnology trait products and herbicides provide farmers with solutions that improve productivity reduce the costs of farming and produce better foods for consumers and better feed for animals. It manages business in two segments: Seeds and Genomics and Agricultural Productivity. Through its Seeds and Genomics segment it produces seed brands including DEKALB Asgrow Deltapine Seminis and De Ruiter and it develops biotechnology traits that assist farmers in controlling insects and weeds. Through its Agricultural Productivity segment it manufactures Roundup brand herbicides and other herbicides and provides lawn-and-garden herbicide products for the residential market.